LEXINGTON, Mass., Jan. 31, 2019 /PRNewswire/ -- Pulmatrix,
Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing and funding of its previously
announced underwritten public offering of 1,561,177 shares of its common stock at a price to the public of $0.17 per share. The gross proceeds from the offering, before deducting the underwriting discounts and
commissions and estimated offering expenses are $265,400.
H.C. Wainwright & Co. acted as the sole book-running manager for the offering.
Pulmatrix currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
A shelf registration statement on Form S-3 (Registration No. 333-212546) relating to the public offering of the shares of
common stock described above was filed with the Securities and Exchange Commission ("SEC") and was declared effective on
August 3, 2016. A prospectus supplement describing the terms of the offering was filed with the SEC
on January 29, 2019, and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the
offering may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue 3rd Floor, New York,
NY 10022, or by calling (646) 975-6996 or by emailing placements@hcwco.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale
of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such jurisdiction. Any offer, if at all, will be made only by means of the
prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary
disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for
serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis
("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and
chronic obstructive pulmonary disease ("COPD"). Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered
dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and
reducing systemic side effects to improve patient outcomes.
Forward-Looking Statements
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking
statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to, the use of net proceeds from the offering and other statements that
are not statements of historical fact, and may be identified by words such as "anticipates," "assumes," "believes," "can,"
"could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects,"
"targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently
available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a
result of certain factors, including, but not limited to, delays in planned clinical trials; the ability to establish that
potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations
on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market
potential products; the ability to obtain future funding for developmental products and working capital and to obtain such
funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A
discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the
Company's filings with the SEC, including its annual report on Form 10-K filed with the Securities and Exchange Commission on
March 13, 2018, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q.
The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/pulmatrix-inc-announces-closing-of-public-offering-of-common-stock-300787708.html
SOURCE Pulmatrix, Inc.